Summary A multicentre randomised phase III trial in chemotherapy-naive patients with advanced non-smallcell lung cancer (NSCLC) was undertaken to compare the therapeutic activity and toxicity of a cisplatin/ carboplatin-etoposide-vinorelbine combination with that of a cisplatin-etoposide regimen. Patients with advanced (stage IIIB-IV) NSCLC were randomised, after stratification for stage (IIIB-IV) and performance status (0-1 and 2), to receive either (A) CDDP 40 mgm 2+VP16 100 mgm-2 on days 1 -3 as standard treatment or (B) CBDCA 250 mgm-2 on day 1 + CDDP 30 mgm-2 on days 2 and 3 + VP16 100 mgm-2 on days 1 -3 + NVB 30 mgm-2 on day 1. Therapy was recycled on day 29 in both arms. We hypothesised a 15% minimum increment in the response rate with the experimental regimen over the 25% expected activity rate of the standard regimen. A two-stage design was chosen, which permitted the early termination of the trial (after the accrual of 52 patients in each arm) if the difference in response rates between the two regimens was less than 3% at the end of the first stage. A total of 112 patients (arm A = 57, arm B = 55) were enrolled in the study (53 with stage IIIB and 59 with stage IV), of which 105 eligible patients were evaluable for response on an 'intention to treat' basis. Seven patients were excluded because they did not fulfil the inclusion criteria. Fifteen responses were observed in arm A (28%, 95% CI = 17-42) and 13 (one complete) in arm B (25%, 95% CI= 13 -37). On multivariate logistic analysis, treatment did not affect the response rate, while stage IV and performance status 2 were significantly associated with a lower probability of response. Median survivals were similar in the two arms (31 vs 27 weeks). The experimental regimen was associated with an extremely poor median survival in patients with poor performance status (21 weeks). On Cox analysis, treatment failed to show a significant impact on survival: stage IV (relative risk= 1.6, CI = 1.0 -2.6, P = 0.036) was the only prognostic variable significantly associated with a worse survival outcome and, although poor performance status adversely affected survival, this effect did not reach the level of statistical significance (relative risk = 1.6, CI=0.98 -2.5; P = 0.063). There were no significant differences in non-haematological toxicities between the two arms, although three patients in the control arm had to discontinue the treatment because of the persistence of severe nephrotoxicity (two patients) or neurotoxicity (one patient). In contrast, a significant increase in both neutropenia and thrombocytopenia was observed in the experimental arm. Four treatmentrelated deaths were registered in arm B (two due to neutropenic sepsis, one to myocardial failure and one to acute renal failure) compared with one toxic death (acute renal failure) in arm A. In view of these results, the trial was stopped and the null hypothesis (< 15% increase in response rate with the experimental regimen) has been accepted. Therefore, our combination does not deserve further evalution as first-line treatment in advanced NSCLC patients. (Boring et al., 1992) . Currently, only a few chemotherapeutic agents have shown a clear activity in patients with non-small-cell lung cancer (NSCLC) (Ihde, 1992 (Faulds, 1992) . Three-drug regimens, consisting of a combination of CDDP and mitomycin with vinca alkaloids or ifosfamide (MVP or MIP) are able to achieve a higher response-rate than the CDDP-VP16 combination (Bunn, 1989) , but their superiority in terms of survival had not until recently been demonstrated in clinical randomised trials . A contemporary trial has yielded conflicting results, only partly explainable by differences in dosage and schedule (Ardizzoni et al., 1995) .
This issue concerning the optimum CDDP dosage is of great relevance in the treatment of NSCLC. A meta-analysis of chemotherapy trials in more than 6247 patients demonstrated a significant correlation between response rate and CDDP dose, with improved activity of high ( 1l00 mg m-2) as opposed to low doses (< lO1 mg m-2) (Donnadieu et al., 1991) . However, at doses )100 mg m-2, CDDP can cause significant neurotoxicity and nephrotoxicity, which may result in discontinuation of its administration, or in early deaths as a result of acute renal failure. In view of this, the partial substitution of CDDP with carboplatin (CBDCA), a CDDP analogue with a better toxicological profile, has been advocated in an attempt to administer a standard or even higher dose of platinum therapy with acceptable toxicity. In a EORTC study, patients were randomised to receive either CDDP alone at the dose of 120 mg m-2 on day 1 or CDDP 30 mg m-2 on days 2 and 3 plus CBDCA 200 mg m-2 on day 1. The response rates were 23% and 22%, respectively, but the combined treatment showed a lower toxicity (Sculier et al., 1994) . The combination of CDDP and CBDCA has also been tested in addition to VP16 with promising results. A 41% response rate was reported in a phase I/II study employing CDDP 80 mg m-2 on day 1, VP16 80 mg m-2 on days 1-3 and CBDCA 280 mg m-2 on day 1 (Tsuchiya et al., 1993) .
Another trial (Sakuray et al., 1993) showed an even higher response rate (57%) in spite of the lower dosages of CDDP (50 mg m-2) and CBDCA (200 mg m-2) used in combination with VP16.
Numerous molecules, other than CDDP and VP16, have been tested in this last decade in an attempt to improve the efficacy of combination chemotherapy against NSCLC. Vinorelbine (VNR) seems one of the most interesting in view of its good activity rate as single agent (Depierre et al., 1989) and of the synergism shown in vitro with both cisplatin and etoposide (Cros et al., 1989) . In a recent three-arm randomised trial (Le Chevalier et al., 1994) , the combination of CDDP and VNR achieved a significantly higher response rate and better survival than the cisplatin-vindesine regimen.
The addition of VNR to the standard CDDP-VP16 combination was tested with promising results (Jacoulet et al., 1991) .
Based on these considerations, we started the present phase III randomised trial. This study aimed to evaluate whether the addition of VNR could significantly improve the therapeutic activity of the CDDP-VP16 combination. In addition, CDDP was partly replaced with CBDCA in the experimental arm, in order to decrease the incidence and severity of CDDP-induced nephrotoxicity and neurotoxicity. Patients WHO criteria (Miller et al., 1981) . It was analysed with respect to the number of patients treated and the number of cycles administered.
Study design and statistical analysis A centralised telephone call procedure was used to assign patients randomly to treatment arm on the basis of a computer-generated list, stratified according to stage and performance status. The aim of the trial was to determine whether the experimental treatment had a 15% higher activity than the control treatment. The average activity rate of standard CDDP-VP16 regimen was taken to be 25%.
The sample size was established by using a two-stage optimal design for phase III trials with binary response (Thall et al., 1988) . This design permitted an early acceptance of the null hypothesis after the first stage (so minimising the expected number of patients to be accrued) if the experimental combination did not have a substantially higher therapeutic activity than the standard regimen. Setting the errors alpha and beta at 5% and 20% respectively, 52 patients for each arm had to be randomised in the first stage. If actual response rate observed in the experimental arm did not exceed that of the control arm by at least 3%, accrual was stopped and the experimental combination rejected. In the opposite case, 75 additional patients had to be accrued in each arm. This stage 1 stopping rule was specified by the equation Pe-P > y1(2pc.qcln1)"2, Pe-Pc defined the difference in response rate observed at the end of the first stage, p, is the chosen activity rate for the control arm, qc = 1 -p, (25% and 75% respectively), nI is the sample size at the first stage (52 patients) and y1 expresses the minimum value of z at first stage to reject the null hypothesis and continue the accrual.
Fisher's exact test was applied for comparison between group frequencies (Fisher et al., 1963) . The main pretreatment variables -performance status (0-1 vs 2), stage (IIIB vs IV), histology (squamous vs others), weight loss > 5 kg (yes vs no) and age (<65 vs ) 65)-together with treatment type were included in a logistic linear model to determine the effect of treatment on response rate when adjusted for the main prognostic features (Fisher, 1950) . Survival curves were plotted using the product-limiting method reported by CDDP/CBDCA+VP16+vinorelbine in advanced NSCLC P Comella et at t 1807 Kaplan et al. (1958 , and their comparisons were made using the log-rank test (Mantel, 1966) . The Cox proportional hazard model (Cox, 1972) (Table IV) . The experimental regimen showed a highly different effect in the two subgroups defined on the basis of performance status. Median survival was 46 weeks in patients with performance status 0 -1 and 21 weeks in those with performance status 2. A particularly high risk of early death was observed in the latter group, as confirmed by the evidence of only a 54% 3 month survival in this group. To the contrary, a different performance status did not translate into a clearly different median survival in the control arm (Figure 2 ). Toxicity Myelosuppression was the most frequent and limiting sideeffect (Table V) . Both neutropenia and thrombocytopenia were significantly more frequent in the experimental arm and two treatment-related deaths as a result of neutropenic sepsis occurred in this arm, compared with no events in the control arm. One patient in the experimental arm had to suspend therapy because of persistent neutropenia. Two patients required platelet transfusion in the experimental arm, but no clinically relevant haemorrhagic episodes were encountered. Grade 4 non-haematological toxicity never occurred, except for vomiting (Table VI) . Nephrotoxicity and ototoxicity were slightly less frequent in arm B, but this improvement was not statistically significant. One patient in each arm died as a consequence of an acute renal failure. Finally, one additional patient in arm B died because of acute myocardial failure. Three patients in arm A discontinued treatment because of persistent nephrotoxicity (two patients) or neurotoxicity (one patient), while only one patient discontinued treatment in arm B because of persistent nephrotoxicity. The actual delivered dose intensity, during the first three courses, was 91% in arm A and 86% in arm B. Taking into account all delivered courses, the mean relative dose intensity was 89% in arm A (CDDP 87%, VP-16 91%) and 83% in arm B (CDDP 81%, CBDCA, VNR and VP-16 84%).
Discussion
An interesting response rate (33%) was reported in a pilot study testing the addition of vinorelbine to the standard cisplatin -etoposide combination, in a population with 10/57 (17)b CDDP/CBDCA+VP16+vinorelbine in advanced NSCLC P Comella et a! particularly poor prognostic factors (Jacoulet et al., 1991) . Moreover, in this study, the response rate increased to over 40% in younger patients or in those with better performance status.
We also previously evaluated the cisplatin -etoposidevinorelbine regimen in a phase 1/11 study, obtaining a very promising response rate (42%) (Comella et al., 1994) . In this trial, we tested the administration of vinorelbine both at the dose of 30 mg m-2 on day and at the dose of 25 mg m-2 on days 1 and 8, however this latter schedule was associated with an unacceptable incidence of grade 3-4 neutropenia.
The present randomised study aimed at evaluating whether this three-drug combination could provide a significant therapeutic advantage (an increase in response rate of at least 15%) over the standard CDDP-VP16 regimen. We decided to partly replace CDDP with CBDCA in the experimental arm in view of the proven similar activity of the two drugs and the better tolerance of CBDCA.
Our results clearly show that this experimental regimen does not substantially improve the prognosis of advanced NSCLC patients, in terms of both response rate and overall survival. We stopped the trial after the first stage because the response rate observed in the experimental arm was even lower than that achieved in the control group, hence we did not fulfil the minimum condition required by our study design (a >3% increase in response rate in the experimental arm) to complete the enrolment. A high number of early treatment failures occurred in the experimental arm, owing mainly to a higher incidence and severity of both neutropenia and thrombocytopenia. It The negative impact of a multidrug treatment with the addition of mitomycin to CDDP-VP16 on poor-prognosis NSCLC patients was also claimed by the Umbria Group (Crino' et al., 1990) to explain the unsatisfactory results reported in the past. In fact, a higher fraction (about 50%) of patients with poor performance status was enrolled in that study as compared with a significantly lower percentage (about 15%) included in a more recent trial carried out by the same authors , which demonstrated a significant increase in both response rate and overall survival with three-drug combinations.
In our study, the CDDP-VP16 treatment showed an acceptable level of activity as regards both response rate (28%) and median survival (31 weeks) . Although the smaller size of our study population renders the 95% confidence interval of response rate quite wide, we think that the true level of activity of the CDDP-VP16 combination probably ranges between a 25% and 30% response rate. The CDDP-VP16 regimen, recycled every 4 weeks, showed a manageable toxicity even in poor-performance status patients, and this resulted in a good therapuetic activity also in this group. On the other hand, our data confirm that this combination is A P Comella et al Langer et al., 1995) . Secondly, more attention should be paid to the host status in the elderly or poor performance status patients. A less toxic chemotherapy, combined with non-cytotoxic drugs CDDP/CBDCA+VP16+vinorelbine in advanced NSCLC P Comella et al e
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(biological response modifiers, lonidamine, melatonine, differentiating agents, etc.) could be the best therapeutic approach in these patients. This approach is probably unable to obtain a dramatic tumour shrinkage in the majority of patients; however, it may be able to delay the progression of the tumour at the price of mild toxicity, resulting in either a longer survival or a better quality of life.
